Herbal capsule could lower heart inflammation in coronary disease

NCT ID NCT06425120

Recruiting now Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether Xuesaitong soft capsules, an herbal medicine, can reduce inflammation and other risk factors in 240 adults with stable coronary heart disease. Participants take either the capsule or a placebo daily for 12 weeks. The main goal is to see if the capsule lowers a key inflammation marker called hsCRP.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xuesaitong soft capsule (herbal medicine)
What this could lead to: If it works, this could provide a new option to reduce inflammation and heart risks for people with coronary heart disease.
What could go wrong: This is a mid-stage trial with only 240 participants, so results may not apply to everyone. The herbal supplement may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY HEART DISEASE

Contacts and locations

Locations

Affiliated Hospital of Nantong University
NOT_YET_RECRUITING

Nantong, Jiangsu, China
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100087, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.